扩张型心肌病伴室性心动过速患者的临床结局
该多中心前瞻性研究纳入281例因室性心动过速接受射频消融的扩张型心肌病患者,随访21个月发现24%死亡或心脏移植,49%室速复发;早期复发且LVEF≤32%者1年死亡或移植率达55%。
要点
- 早期室速复发且LVEF≤32%者死亡或心脏移植风险极高,应考虑机械支持或移植筛查。
- 晚期室速复发不预测更差结局,而早期复发、出院服胺碘酮、肾功能不全及LVEF是死亡或移植的独立预测因素。
- 既往ICD放电、基底前间隔室速起源及手术失败预测室速复发,但LVEF不预测复发。
核心结论
- 因室速需射频消融的扩张型心肌病患者为高风险群体,约半数术后无室速复发。
- 早期室速复发且LVEF≤32%者死亡或心脏移植风险极高,应考虑机械支持或移植筛查。
- 射频消融后晚期室速复发不预测更差结局。
研究设计与样本
- 多中心前瞻性队列研究,连续纳入9个中心因室速接受射频消融的扩张型心肌病患者281例。
- 平均年龄60±13岁,男性占85%,平均左心室射血分数(LVEF)36%±12%。
主要发现
- 随访21个月(IQR 6-30个月)期间,67例(24%)死亡或接受心脏移植,138例(49%)室速复发,其中45例为早期复发(30天内)。
- 4年室速复发或死亡或心脏移植率为70%。
- 死亡或心脏移植的独立预测因素包括早期室速复发(HR 2.92;95%CI 1.37-6.21;P<0.01)、出院时使用胺碘酮(HR 3.23;95%CI 1.43-7.33;P<0.01)、肾功能不全(HR 1.92;95%CI 1.01-3.64;P=0.046)及LVEF(HR 1.36;95%CI 1.0-1.84;P=0.052)。
- LVEF≤32%可识别死亡或心脏移植风险(AUC 0.75)。
- 早期复发后每100人年死亡或心脏移植事件数为40.4,晚期复发后为14.2,无复发为8.5(两者P<0.01)。
关键数值与推荐
- LVEF≤32%为死亡或心脏移植的风险识别阈值(AUC 0.75)。
- 早期室速复发定义为射频消融后30天内复发。
临床怎么用
- 对因室速接受射频消融的扩张型心肌病患者,应识别早期复发且LVEF≤32%的高危人群并考虑机械支持或心脏移植筛查。
- 出院时使用胺碘酮、肾功能不全及较低LVEF提示死亡或移植风险增高。
- 晚期室速复发不提示更差结局,临床管理可据此调整随访强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent ventricular tachycardia (VT) due to dilated cardiomyopathy (DCM) is difficult to treat, and long-term outcome data are limited. OBJECTIVES: The aim of this study was to identify predictors of mortality or heart transplantation (HTx) and VT recurrence. METHODS: Consecutive patients with DCM accepted for radiofrequency catheter ablation (RFCA) of VT at 9 centers were prospectively enrolled and followed. RESULTS: Of 281 consecutive patients (mean age 60 ± 13 years, 85% men, mean left ventricular ejection fraction [LVEF] 36% ± 12%), 35% had VT storm, 20% had incessant VT, and amiodarone was unsuccessful in 68%. During follow-up of 21 months (IQR: 6-30 months), 67 patients (24%) died or underwent HTx, and 138 (49%) had VT recurrence (45 within 30 days, defined as early); the 4-year rate of VT recurrence or mortality or HTx was 70%. Independent predictors of mortality or HTx were early VT recurrence (HR: 2.92; 95% CI: 1.37-6.21; P < 0.01), amiodarone at discharge (HR: 3.23; 95% CI: 1.43-7.33; P < 0.01), renal dysfunction (HR: 1.92; 95% CI: 1.01-3.64; P = 0.046), and LVEF (HR: 1.36; 95% CI: 1.0-1.84; P = 0.052). LVEF ≤32% identified patients at risk for mortality or HTx (area under the curve: 0.75). Mortality or HTx per 100 person-years was 40.4 events after early, compared with 14.2 events after later VT recurrence and 8.5 events with no VT recurrence after RFCA (P < 0.01 for both). Patients with early recurrence and LVEFs ≤32% had a 1-year rate of mortality or HTx of 55%. VT recurrence was predicted by prior implantable cardioverter-defibrillator shocks, basal anteroseptal VT origin, and procedural failure but not LVEF. CONCLUSIONS: Patients with DCM needing RFCA for VT are a high-risk group. Following RFCA, approximately one-half remain free of VT recurrence. Early VT recurrence with LVEF ≤32% identifies those at very high risk for mortality or HTx, and screening for mechanical support or HTx should be considered. Late VT recurrence after RFCA does not predict worse outcome.
引用
- Zeppenfeld K, Wijnmaalen AP, Ebert M, et al. Clinical Outcomes in Patients With Dilated Cardiomyopathy and Ventricular Tachycardia. J Am Coll Cardiol. 2022. PMID: 36075673. doi:10.1016/j.jacc.2022.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。